IPP Bureau
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
By IPP Bureau - June 02, 2025
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
By IPP Bureau - May 31, 2025
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Paras Health Gurugram raises alarm over surge in tobacco-related cancers
By IPP Bureau - May 31, 2025
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Pfizer’s Braftovi combination regime reduces death risk for patients with BRAF V600E mutant mCRC
By IPP Bureau - May 31, 2025
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Merck’s MK-1084 shows antitumor activity in Phase 1 trial of patients with advanced colorectal cancer
By IPP Bureau - May 31, 2025
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
Procter & Gamble Hygiene and Health Care posts Q3 FY25 PAT at Rs. 156 Cr
By IPP Bureau - May 30, 2025
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Alkem reports 7.1% YoY revenue growth in Q4 FY25
By IPP Bureau - May 30, 2025
Annual EBITDA margin expands by 170 basis points
Sudeep Pharma acquires Nutrition Supplies Services
By IPP Bureau - May 30, 2025
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
Merck withdraws Biologics License Application for Patritumab Deruxtecan
By IPP Bureau - May 30, 2025
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer
By IPP Bureau - May 29, 2025
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Pimicotinib demonstrates best-in-class potential with significant efficacy and clinically meaningful improvements in patients with tenosynovial giant cell tumor
By IPP Bureau - May 29, 2025
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
USV’s ‘United for BP Control’ Mission takes aim at India’s blood pressure epidemic
By IPP Bureau - May 29, 2025
The initiative was announced at World Hypertension Congress, Chennai
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
By IPP Bureau - May 29, 2025
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
By IPP Bureau - May 28, 2025
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
